Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute describes what it takes to deliver combination therapy for epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC) outside a trial, crediting financial advocates, social workers, nurses and pharmacists.
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents a 74-year-old woman with epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), no central nervous system involvement, limited mobility, osteoporosis and rheumatoid arthritis, who lives alone an hour from the cancer center and depends on others for transportation.
Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute says he tries not to push patients with asymptomatic brain metastases from epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC) toward local therapy, calling whole brain radiation the wrong step for this patient and noting that another consultation costs the patient time.
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents a 68-year-old woman with newly diagnosed metastatic lung adenocarcinoma, an epidermal growth factor receptor (EGFR) exon 19 deletion with a concurrent TP53 co-mutation, multiple small asymptomatic brain metastases on staging magnetic resonance imaging, disease confined to lung and brain, and good performance status with support at home.
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents long-term resistance data from the phase 3 MARIPOSA study in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), where amivantamab plus lazertinib reduced acquired MET amplification approximately fourfold and secondary EGFR resistance mutations approximately fivefold compared with osimertinib.
Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute says he sees no remaining role for intravenous amivantamab in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), with subcutaneous administration taking 10 to 15 minutes and easing chair time and scheduling.
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center describes COPERNICUS, a pragmatic study of first-line subcutaneous amivantamab plus lazertinib with protocol-directed supportive care in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), which was open at her own site.
Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute rejects the idea that a TP53 co-mutation points toward chemotherapy in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC).
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center contrasts central nervous system (CNS) imaging in the phase 3 MARIPOSA and FLAURA2 studies of epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), noting that one scanned every patient on a set schedule while the other continued imaging mainly in patients with baseline brain metastases.
Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute pushes back on the high-risk label in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), noting that when 89% of patients with analyzable circulating tumor DNA in the phase 3 MARIPOSA study carry at least 1 high-risk feature, the term loses meaning.
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents the final overall survival data from the phase 3 FLAURA2 study of osimertinib plus chemotherapy in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), at more than 47.5 months versus approximately 38 months for osimertinib alone, and asks how the panel handles cross-trial comparison.
Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute and Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute discuss how they translate grade 3 or higher adverse event rates into a conversation a patient can actually use in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC).
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center walks through the mature overall survival data from the phase 3 MARIPOSA study of amivantamab plus lazertinib in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC).
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center opens this CancerNetwork Around the Practice discussion on first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC) with panelists Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute, and Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute.
In this closing segment, the panel reflects on ongoing unmet needs in the first line management of EGFR mutated metastatic non-small cell lung cancer.
In this segment, the discussion returns to the theme of long term management in EGFR mutated metastatic non-small cell lung cancer.
In this segment, Dr. Devarakonda asks Dr. Rotow to address the role of dose interruptions and reductions in managing treatment related toxicities in EGFR mutated metastatic non-small cell lung cancer.
In this segment, the discussion shifts to a 70 year old patient with EGFR mutated metastatic non-small cell lung cancer who is experiencing dermatologic toxicity several months into first line EGFR targeted therapy.
In this segment, the panel further examines the case of a patient with EGFR mutated metastatic non-small cell lung cancer and asymptomatic brain metastases.
In this case based segment, Dr. Devarakonda introduces a newly diagnosed 62 year old patient with EGFR exon 19 deleted metastatic non-small cell lung cancer and asymptomatic brain metastases.
In this segment, the panel discusses how complex treatment education is operationalized in routine practice for patients with EGFR mutated metastatic non-small cell lung cancer.
In this segment, Dr. Devarakonda asks Dr. Rous to explore how treatment schedules and dosing flexibility influence shared decision making and long term adherence in EGFR mutated metastatic non-small cell lung cancer.
In this segment, the discussion centers on proactive toxicity management strategies in EGFR mutated metastatic non-small cell lung cancer.
In this segment, Dr. Devarakonda asks Dr. Rous to interpret the clinical implications of the FDA approval of subcutaneous amivantamab in combination with lazertinib, including the availability of once monthly dosing.
In this segment, Dr. Devarakonda asks Dr. Singhi to address how route of administration and treatment logistics influence clinical decision making in EGFR mutated metastatic non-small cell lung cancer.
In this segment, Dr. Devarakonda asks Dr. Rotow to move beyond clinical trial data and discuss the real world factors that influence first line treatment selection in EGFR mutated metastatic non-small cell lung cancer.
In this segment, Dr. Devarakonda asks Dr. Rotow to outline the advantages and limitations of combination regimens compared with single agent EGFR tyrosine kinase inhibitors in the first line treatment of EGFR mutated metastatic non-small cell lung cancer.
In this segment, Dr. Devarakonda invites the panel to reflect on how updated clinical guidelines are shaping first line treatment patterns in EGFR mutated metastatic non-small cell lung cancer.
Experts weigh EGFR lung cancer combo therapies, cautioning against cross-trial comparisons and prioritizing CNS efficacy for brain metastases.
Experts unpack new EGFR-mutant lung cancer first-line options, weighing survival, CNS control, and toxicity as combo regimens reshape practice.
